How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/familial-hypercholesterolemia-heterozygous.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Familial hypercholesterolemia - heterozygous — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Familial hypercholesterolemia - heterozygous (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Familial hypercholesterolemia - heterozygous, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Leqvio	INCLISIRAN	Novartis		Proprotein convertase subtilisin/kexin type 9	2021-01-01
Nexletol	BEMPEDOIC ACID	Esperion Theraps Inc	Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC]	ATP-citrate lyase (ACL), Niemann-Pick C1-Like 1 (NPC1L1)	2020-01-01
Repatha	EVOLOCUMAB	Repatha	PCSK9 Inhibitor [EPC]	PCSK9	2015-01-01
Praluent	ALIROCUMAB	Sanofi	PCSK9 Inhibitor [EPC]	Proprotein convertase subtilisin/kexin type 9	2015-01-01
Trilipix	CHOLINE FENOFIBRATE	AbbVie	Peroxisome Proliferator Receptor alpha Agonist	Fatty acid-binding protein, intestinal	2008-01-01
Crestor	rosuvastatin	AstraZeneca	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Zetia	EZETIMIBE	Merck & Co.	HMG-CoA Reductase Inhibitor [EPC]	Niemann-Pick C1-like protein 1	2002-01-01
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lipitor	Atorvastatin Calcium	Pfizer	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Lescol	FLUVASTATIN	Novartis	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 3 drugs in Familial hypercholesterolemia - heterozygous
Novartis · 2 drugs in Familial hypercholesterolemia - heterozygous
Cedars-Sinai Medical Center · 1 drug in Familial hypercholesterolemia - heterozygous
Esperion Theraps Inc · 1 drug in Familial hypercholesterolemia - heterozygous
MEDPOINTE PHARM HLC · 1 drug in Familial hypercholesterolemia - heterozygous
Medpointe Pharm Hlc · 1 drug in Familial hypercholesterolemia - heterozygous
NVP Healthcare · 1 drug in Familial hypercholesterolemia - heterozygous
Pfizer · 1 drug in Familial hypercholesterolemia - heterozygous
Pfizer Inc. · 1 drug in Familial hypercholesterolemia - heterozygous
Regeneron Pharmaceuticals · 1 drug in Familial hypercholesterolemia - heterozygous
Repatha · 1 drug in Familial hypercholesterolemia - heterozygous
Salix · 1 drug in Familial hypercholesterolemia - heterozygous

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Familial hypercholesterolemia - heterozygous:

Cite this brief

Drug Landscape (2026). Familial hypercholesterolemia - heterozygous — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/familial-hypercholesterolemia-heterozygous. Accessed 2026-06-10.

Familial hypercholesterolemia - heterozygous full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing